Oxazepam
| Oxazepam | |
|---|---|
| Salts [] | |
|---|---|
| Sodium oxazepam | |
| Potassium oxazepam | |
| Oxazepam hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 286.71 g/mol [1] |
| Appearance | Crystals from alcohol [1] |
| Odor | PRACTICALLY ODORLESS [1] |
| Taste | BITTER [1] |
| Melting point | 401 to 403 °F (NTP, 1992) [1] |
| Solubility | less than 1 mg/mL at 66 °F (NTP, 1992) [1] |
| Predicted LogP | 2.2 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C15H11ClN2O2 |
| IUPAC name | 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one |
| SMILES | C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O |
| InChI | InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19) |
| InChIKey | ADIMAYPTOBDMTL-UHFFFAOYSA-N |
| CAS number | 604-75-1 |
| UNII | 6GOW6DWN2A |
| PubChem CID | 4616 |
| Pharmacokinetics[] | |
|---|---|
| Onset | 30 - 120 minutes |
| Elimination half-life | 6–9 hours[3][4][5] |
| Duration of action | 6 - 12 hours |
| Metabolism | Hepatic (glucuronidation) |
| Excretion | Renal |
| Routes of administration | By mouth |
| Dependence liability | Moderate |
| Addiction liability | Low–moderate |
| Toxicity [] | |
|---|---|
| LD50 | Rat: - oral: 5 g/kg [1] |
Oxazepam (also known as Serax, Tazepam, Adumbran, Droxacepam, Serenid, Serepax, Seresta, Zaxopam, Rondar or Sobril) is a steroid substance of the aniline and benzodiazepine class.
Chemistry
Salts []
Stereochemistry []
Oxazepam is a racemic mixture of the enantiomers (optical activity ( + / - )).
| Stereoisomerism |
|---|
| Stereoisomers from PubChem |
Druglikeness
Lipinski's rule of five
Oxazepam matches Lipinski's rule of five.Reagents
There are currently 1 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Mecke | light yellow / lemon yellow |
Pharmacology
ATC Classification
- nervous system (N)
- psycholeptics (N05)
- anxiolytics (N05B)
- benzodiazepine derivatives (N05BA)
- (N05BA04)
- oxazepam (N05BA04)
MeSH Classification
Mechanism of action []
Like other benzodiazepines, oxazepam exerts its anxiolytic effects by potentiating the effect of gamma-aminobutyric acid (GABA) on GABA(A) receptors, the main inhibitory neurotransmitter receptors in the mammalian brain. GABA(A) receptors are a component of GABA-gated ionotropic chloride channels that produce inhibitory postsynaptic potentials - following activation by GABA, the channel undergoes a conformational change that allows the passage of chloride ions through the channel. The inhibitory potentials produced by GABA neurotransmission play an integral role in the suppression and control of epileptiform nerve firing such as that seen in epilepsy, which makes the GABA system a desirable target in the treatment of epilepsy. Benzodiazepines are positive allosteric modulators of GABA(A) function. They bind to the interface between alpha (α) and gamma (γ) subunits on the receptor, commonly referred to as the benzodiazepine binding site, and modulate the receptor such that its inhibitory response to GABA binding is dramatically increased. [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| GABRA1 | shared target | 7 |
|---|---|---|
| GABRA2 | shared target | 7 |
| GABRA3 | shared target | 7 |
| GABRA4 | shared target | 7 |
| GABRA5 | shared target | 7 |
| GABRA6 | shared target | 7 |
| GABRB1 | shared target | 7 |
| GABRB2 | shared target | 7 |
| GABRB3 | shared target | 7 |
| GABRD | shared target | 7 |
| GABRE | shared target | 7 |
| GABRG1 | shared target | 7 |
| GABRG2 | shared target | 7 |
| GABRG3 | shared target | 7 |
| GABRP | shared target | 7 |
| GABRQ | shared target | 7 |
Medical side effects []
40 side effects listed on drug labels in SIDER 4.1 (oxazepam).
- Abdominal pain
- Gastrointestinal pain
- Aggression
- Agranulocytosis
- Ataxia
- Diplopia
- Dizziness
- Syncope
- Somnolence
- Oedema
- Dermatitis
- Rash
- Body temperature increased
- Hallucination
- Headache
- Blood disorder
- Hypersensitivity
- Hypotension
- Incontinence
- Jaundice
- Lethargy
- Leukopenia
- Nausea
- Paraesthesia
- Shock
- Loss of consciousness
- Tremor
- Vertigo
- Stupor
- Depressed level of consciousness
- Hepatic function abnormal
- Menstruation irregular
- Drug eruption
- Disorientation
- Agitation
- Memory impairment
- Amnesia
- Dysarthria
- Euphoric mood
- Vision blurred
Indications
- Agitation
- Alcohol intoxication
- Alcohol withdrawal syndrome
- Anxiety
- Anxiety disorder
- Confusional state
- Irritability
- Tension
- Tremulousness
Subjective effects []
Experience reports
Legal status []
- Australia: Oxazepam is a Schedule 4.
- Brazil: Oxazepam is a B1.[6]
- Canada: Oxazepam is a Schedule IV.
- Germany: Oxazepam is Prescription only/Anlage III.
- United States: Oxazepam is a Schedule IV under the "Controlled Substances Act".
- European Union: Oxazepam is Prescription only.
- Other: Oxazepam is a SE: Förteckning IV.[7][8]
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 4616, Oxazepam. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/4616
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Oxazepam. UNII: 6GOW6DWN2A. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/6GOW6DWN2A
Encadré 1. Anxiolytiques à demi-vie courte (< 20 heures) et sans métabolite actif par ordre alphabétique de DCI. Has-sante.fr. https://www.has-sante.fr/upload/docs/application/pdf/2011-11/mama_troubles_comportement_encadre_1_anxiolitiques.pdf
Sonne J, Loft S, Døssing M, Vollmer-Larsen A, Olesen KL, Victor M, Andreasen F, Andreasen PB. Bioavailability and pharmacokinetics of oxazepam. European Journal of Clinical Pharmacology. 1988; 35(4):385–389. PMID 3197746. https://doi.org/10.1007/bf00561369
Sonne J, Boesgaard S, Poulsen HE, Loft S, Hansen JM, Døssing M, Andreasen F. Pharmacokinetics and pharmacodynamics of oxazepam and metabolism of paracetamol in severe hypothyroidism. British Journal of Clinical Pharmacology. November 1990; 30(5):737–742. PMID 2271373. https://doi.org/10.1111/j.1365-2125.1990.tb03844.x
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Oxascand, Tablett 10 mg. FASS. 23 August 2024. https://fass.se/health/product/19880219000019/fass-text
Delipam, Tablett 10 mg. FASS. 29 September 2025. https://fass.se/health/product/20220421000036/fass-text
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 07:36:15 |
| drugspro | ok | 2026-11-20 07:36:11 |
| erowid | ok | 2026-11-20 07:36:13 |
| gsrs | ok | 2026-11-20 07:36:13 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0014980) | 2026-11-20 07:36:11 |
| kegg | ok | 2026-11-20 07:36:13 |
| pubchem | ok | 2026-11-20 07:36:08 |
| ok | 2026-11-20 07:36:11 | |
| sider | ok | 2026-11-20 07:36:11 |
| structure | ok | 2026-11-20 07:36:11 |
| wikipedia | ok | 2026-11-20 07:36:11 |